生理药代动力学模型量化慢性肾病对OAT1/3活性的影响
本研究利用生理药代动力学模型,以阿昔洛韦、美罗培南、呋塞米和环丙沙星四种OAT1/3底物为对象,量化慢性肾病各阶段OAT1/3介导药物分泌的下降程度。结果显示,CKD3、4、5期OAT1/3介导的肾排泄分别下降27-49%、50-68%和70-96%;模型能较好预测不同肾功能损害患者的药代动力学。
要点
- CKD3/4/5期OAT1/3介导药物分泌分别下降27-49%、50-68%、70-96%。
- 基于四种底物构建的PBPK模型预测总暴露在1.5倍误差内,85%数据点符合。
- 模型对间歇性血液透析的ESRD患者血浆浓度略有低估,需谨慎解读。
核心结论
- 慢性肾病各阶段OAT1/3介导的药物肾排泄显著下降,且下降幅度随CKD分期加重而增大。
研究设计与样本
- 基于四种OAT1/3底物(阿昔洛韦、美罗培南、呋塞米、环丙沙星)构建生理药代动力学模型,利用丙磺舒药物相互作用数据参数化OAT1/3贡献,并转化至CKD患者。
- 通过不同肾功能损害患者对氨基马尿酸肾提取率推导eGFR与OAT1/3介导分泌下降的关系,并在计算机中评估模型预测性能。
主要发现
- CKD3期OAT1/3介导药物肾排泄下降27-49%,CKD4期下降50-68%,CKD5期下降70-96%。
- 四种底物的PBPK模型能充分描述不同肾功能损害患者的PK,静脉给药后总暴露预测在1.5倍误差内,85%观测数据点落在1.5倍预测误差内。
- 模型对接受间歇性血液透析的ESRD患者血浆浓度略有低估。
关键数值与推荐
- OAT1/3介导肾排泄下降幅度:CKD3期27-49%,CKD4期50-68%,CKD5期70-96%。
- 模型预测总暴露在1.5倍误差内,85%观测数据点落在1.5倍预测误差内。
临床怎么用
- 临床药学智能体可参考OAT1/3介导分泌下降的定量关系,辅助预测CKD患者经OAT1/3排泄药物的暴露变化。
- 对CKD3-5期患者使用OAT1/3底物药物时,应关注因分泌下降导致的暴露增加风险,但具体剂量调整需结合药物说明及临床监测。
局限性
- 分析的分子数量有限。
- 观察性CKD药代动力学研究采样稀疏。
- 模型对间歇性血液透析的ESRD患者血浆浓度略有低估,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The renal excretion of drugs via organic anion transporters 1 and 3 (OAT1/3) is significantly decreased in patients with renal impairment. This study uses physiologically based pharmacokinetic models to quantify the reduction in OAT1/3-mediated secretion of drugs throughout varying stages of chronic kidney disease. METHODS: Physiologically based pharmacokinetic models were constructed for four OAT1/3 substrates in healthy individuals: acyclovir, meropenem, furosemide, and ciprofloxacin. Observed data from drug-drug interaction studies with probenecid, a potent OAT1/3 inhibitor, were used to parameterize the contribution of OAT1/3 to the renal elimination of each drug. The models were then translated to patients with chronic kidney disease by accounting for changes in glomerular filtration rate, kidney volume, renal blood flow, plasma protein binding, and hematocrit. Additionally, a relationship was derived between the estimated glomerular filtration rate and the reduction in OAT1/3-mediated secretion of drugs based on the renal extraction ratios of ƿ-aminohippuric acid in patients with varying degrees of renal impairment. The relationship was evaluated in silico by evaluating the predictive performance of each final model in describing the pharmacokinetics (PK) of drugs across stages of chronic kidney disease. RESULTS: OAT1/3-mediated renal excretion of drugs was found to be decreased by 27-49%, 50-68%, and 70-96% in stage 3, stage 4, and stage 5 of chronic kidney disease, respectively. In support of the parameterization, physiologically based pharmacokinetic models of four OAT1/3 substrates were able to adequately characterize the PK in patients with different degrees of renal impairment. Total exposure after intravenous administration was predicted within a 1.5-fold error and 85% of the observed data points fell within a 1.5-fold prediction error. The models modestly under-predicted plasma concentrations in patients with end-stage renal disease undergoing intermittent hemodialysis. However, results should be interpreted with caution because of the limited number of molecules analyzed and the sparse sampling in observed chronic kidney disease pharmacokinetic studies. CONCLUSIONS: A quantitative understanding of the reduction in OAT1/3-mediated excretion of drugs in differing stages of renal impairment will contribute to better predictive accuracy for physiologically based pharmacokinetic models in drug development, assisting with clinical trial planning and potentially sparing this population from unnecessary toxic exposures.
引用
- Dubinsky S, Malik P, Hajducek DM, et al. Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet. 2022. PMID: 35508593. doi:10.1007/s40262-022-01121-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。